Quest Diagnostics Incorporated $DGX Shares Sold by Midwest Trust Co

Midwest Trust Co lessened its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 5.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 94,573 shares of the medical research company’s stock after selling 5,691 shares during the quarter. Midwest Trust Co owned approximately 0.09% of Quest Diagnostics worth $18,024,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. MTM Investment Management LLC purchased a new position in Quest Diagnostics during the second quarter worth about $29,000. True Wealth Design LLC increased its stake in shares of Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 122 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of Quest Diagnostics by 18,400.0% during the 2nd quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after acquiring an additional 184 shares during the period. First Horizon Corp acquired a new stake in shares of Quest Diagnostics in the third quarter worth approximately $33,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of Quest Diagnostics in the second quarter worth approximately $35,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

DGX has been the topic of a number of recent analyst reports. Morgan Stanley set a $207.00 price target on shares of Quest Diagnostics and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Mizuho increased their target price on Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Quest Diagnostics in a report on Monday, December 29th. Piper Sandler upped their price target on Quest Diagnostics from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Finally, Jefferies Financial Group lifted their price objective on Quest Diagnostics from $200.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, October 21st. Eight research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $198.50.

Quest Diagnostics Stock Up 0.3%

Shares of Quest Diagnostics stock opened at $191.30 on Tuesday. Quest Diagnostics Incorporated has a 1-year low of $157.20 and a 1-year high of $197.55. The company has a market capitalization of $21.28 billion, a PE ratio of 22.45, a P/E/G ratio of 2.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.13 and a quick ratio of 1.04. The business has a 50-day moving average of $181.33 and a 200-day moving average of $181.51.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the sale, the director owned 17,037 shares in the company, valued at $3,267,015.12. This trade represents a 6.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark E. Delaney sold 7,946 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total value of $1,488,683.10. Following the completion of the transaction, the senior vice president directly owned 7,530 shares in the company, valued at approximately $1,410,745.50. The trade was a 51.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 64,289 shares of company stock worth $12,318,360 in the last 90 days. 8.16% of the stock is owned by corporate insiders.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.